Document Detail

Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction.
MedLine Citation:
PMID:  17903051     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Stem cell transplantation after myocardial infarction has been claimed to restore cardiac function. Mesenchymal stem cells attract a lot of attention because of the feasibility of in vivo and ex vivo differentiation to cardiomyocytes and endothelial cells as well as their trophic effect on tissue repair. In this study, we investigated the efficacy of autologous bone marrow derived mesenchymal stem cells in improving heart function in patients with old myocardial infarction.
METHODS: Eight patients with old myocardial infarction and proper inclusion criteria were injected with mesenchymal stem cells at the time of coronary artery bypass grafting or percutaneous coronary intervention (test group) and compared with eight matched patients who received the same treatment without mesenchymal stem cell injection (control group). Evaluation of heart function was done by echocardiography plus single-photon emission computed tomography before and six months after the procedure. Serial clinical examination was performed every month through New York Heart Association class.
RESULTS: The mean New York Heart Association class and single-photon emission computed tomography scan results decreased significantly in the test group (P=0.000 and 0.002, respectively) and in the control group (P=0.049 and 0.007, respectively) after the procedure at six months follow-up. Left ventricular ejection fraction increased significantly in the test group (P= 0.005) but not in the control group. In comparison between the test and control groups the results of New York Heart Association class assessment and single-photon emission computed tomography demonstrated significant improvement in the test group (P=0.005 and 0.013, respectively). There were no significant differences between the baseline variables in the two groups.
CONCLUSION: Transplantation of ex vivo expanded bone marrow derived mesenchymal stem cell in patients with old myocardial infarction is a safe and feasible procedure. These cells improve the cardiac function without serious adverse effects.
Mandana Mohyeddin-Bonab; Mohamad-Reza Mohamad-Hassani; Kamran Alimoghaddam; Mehdi Sanatkar; Masuod Gasemi; Hamid Mirkhani; Hassan Radmehr; Mehrdad Salehi; Massoud Eslami; Amir Farhig-Parsa; Hassan Emami-Razavi; Mahmood Gholam Alemohammad; Mahmood Ghasemi al-Mohamad; Ali-Akbar Solimani; Ardeshir Ghavamzadeh; Behrouz Nikbin
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Archives of Iranian medicine     Volume:  10     ISSN:  1029-2977     ISO Abbreviation:  Arch Iran Med     Publication Date:  2007 Oct 
Date Detail:
Created Date:  2007-10-01     Completed Date:  2008-01-17     Revised Date:  2013-05-15    
Medline Journal Info:
Nlm Unique ID:  100889644     Medline TA:  Arch Iran Med     Country:  Iran    
Other Details:
Languages:  eng     Pagination:  467-73     Citation Subset:  IM    
Immunogenetics Laboratory, Department of Immunology, Tehran University of Medical Sciences, Tehran, Iran.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Case-Control Studies
Cell Proliferation
Cells, Cultured
Follow-Up Studies
Heart Function Tests
Mesenchymal Stem Cell Transplantation*
Mesenchymal Stromal Cells / cytology*
Middle Aged
Myocardial Infarction / physiopathology,  therapy*
Receptors, Immunologic / metabolism
Transplantation, Autologous
Reg. No./Substance:
0/Receptors, Immunologic
Comment In:
Arch Iran Med. 2007 Oct;10(4):435-8   [PMID:  17903046 ]
Erratum In:
Arch Iran Med. 2008 Mar;11(2):241
Note: al-Mohamad, Mahmood Ghasemi [corrected to Alemohammad, Mahmood Gholan]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decom...
Next Document:  A method for isolation and cultivation of adult Schwann cells for nerve conduit.